Tesaro, Inc. (NASDAQ: TSRO) markets a highly successful therapy for ovarian cancer, Zejula, and its plans for the future include winning approval of Zejula's use alongside another one of its drugs, TSR-042, in non-small cell lung cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,